Proven Study Results

Ultraclean Surgery with Illuvia®

Joint Infection from 1.9% to 0%

Significant Bacteria Load Decrease

Decreased bacterial load by 40% under routine care in an emergency department.

Reduced Airborne Contamination

58-81% reductions of total and viable biological airborne contamination.

 

The Consensus is in: Reduce OR airborne contamination now.

Leaders at the International Consensus Meeting on Musculoskeletal Infection agreed by a 94% consensus, stating: “The amount of airborne contamination in the active operating room should be minimized to prevent surgical site infection/PJI.”

“When I shop for a hospital I want the best. Good hospitals wash hands and mop the floor. Best hospitals clean the air all around us.”

Nice deep breaths… While I’m asleep, airborne germs are awake. I can rest easy knowing my hospital is using the latest technology to remove germs from the air. ”

Aerobiotix.

Leading the way for safer environments for patients and caregivers.

Nice deep breaths...

“While I’m asleep, airborne germs are awake. I can rest easy knowing my hospital is using the latest technology to remove germs from the air.”

Elevated bacterial content in OR air causes increased surgical site infection rates.

Aerobiotix Prospective randomized multicenter study results shows that joint replacement procedures performed in rooms with over 50 CFU/m³ airborne bacterial colony forming units per cubic meter were 2.6 times as likely to have postoperative SSI than those done in cleaner air with 20 CFU/m³.

– OM LIDWELL, JOURNAL OF HOSPITAL INFECTION

Keeping Hospitals Safe

Illuvia® HEPA – Ultraviolet Air recirculation system (HUAIRS®)

Hospital air is contaminated with airborne microbes which can cause dangerous surgical site infections. Learn how the Illuvia® system is keeping patients safe.

News and Events

News and Events

CLEANER AIR MEANS BETTER HEALTHCARE

Surgical site infections (SSIs) continue to constitute a significant fraction of hospital-acquired infections contributing to morbidity and mortality to healthcare systems globally. There are approximately 290,000 incidences of SSIs in the USA alone each year, translating into economic loss of $8.36 billion. A significant portion of SSIs have been proven to be airborne in origin and correlate with increased bacterial air content.

The International Consensus Meeting on Musculoskeletal Infection is the definitive meeting of global leaders in orthopedic infection. Chaired by Dr. Javad Parvizi, the latest meeting was July 2018 in Philadelphia and attended by over 400 delegates.

By a 94% consensus, these leaders stated that: “the amount of airborne contamination in the active operating room should be minimized to prevent surgical site infection/PJI.” Only Illuvia HUAIRS is designed to reduce the possibility of surgical infections by decontaminating intraoperative air with a combination of advanced ultraviolet and HEPA technologies.

"Eliminates at least 99.97% of bacteria in single-pass testing."

Center for Microbial Community Studies; Research Triangle Institute

"There is a good correlation between air contamination and joint sepsis rate."

OM Lidwell; Journal of Hospital Infection

"Reduces O.R. air bacterial levels by over 60%."

Surgical Infection Society National Meeting 2017

"Reduced the total and viable airborne particulates as well as colony forming units (CFU) per cubic meter in orthopaedic operating theatre."

– Surgical & Orthopaedic Research Laboratories University of New South Wales

"C-UVC units significantly reduce total and viable particle counts"

– The Journal of Arthroplasty, 2017

A consensus of 94% agree that the amount of airborne contamination in the active operating room should be minimized to prevent SSI/PJI.

– Second Annual International Consensus Meeting on Musculoskeletal Infection 2018

 

Contact Us

 

444 Alexandersville Rd
Miamisburg, Ohio 45342

info@aerobiotix.com
+1 888 978 7087

=

JASON-TODD-VP-SALES-AEROBIOTIX

JASON TODD

Vice President of Global Sales

Jason leads our global sales team and brings over 18 years of Medical Device experience to Aerobiotix. Jason has led top performing National and Regional Sales teams, selling disruptive technology in the Cardiovascular space with Getinge, Surgical Robotics at Hansen Medical and most recently in the Biologics space with Axogen. Jason received his Bachelor of Science Degree from the University of Indianapolis.

MELISSA-GIETZEN-VP-GLOBAL-MARKETING-AEROBIOTIX

MELISSA GIETZEN, MBA

Vice President of Global Marketing

Melissa Gietzen, MBA is a highly skilled strategic marketing professional with over 20 years’ experience in the healthcare industry. She has significant expertise in strategic planning, capital budgeting, service improvement projects, and creating strong successful brands in the orthopedic, cardiac & ophthalmology markets. Melissa holds a undergraduate degree in Management and Organization Development and a masters degree in Business Administration.

DAVID KIRSCHMAN, M.D. President and CEO

DAVID KIRSCHMAN, M.D.

President and CEO

The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.

GREGORY CARROLL PH.D. Director Scientific Affairs

GREGORY CARROLL PH.D.

Director Scientific Affairs

Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.

TONY EMBREE Chief Commercial Officer

TONY EMBREE

Chief Commercial Officer

Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.

COURTNEY ADAMS, Ph.D. VP of Clinical and Medical Affairs

COURTNEY ADAMS, Ph.D.

VP of Clinical and Medical Affairs

Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.

ANTHONY DEFALCO Vice President of Engineering

ANTHONY DEFALCO

Vice President of Engineering

Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.

NATHAN UTZ Vice President of Client Services

NATHAN UTZ

Vice President of Client Services

Nathan brings a high level of commitment to servicing and building client relations. Nathan has previously held leadership roles in the medical device industry.

MICHAEL SCHMITZ Chief Financial Officer

MICHAEL SCHMITZ

Chief Financial Officer

Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.